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Abstract 
HIV-infected patients from moderate regions who travel in tropical countries may experience clinical 
disease progression due to exposure to bacteria (including mycobacteria), fungi and parasites. In the Swiss 
HIV Cohort Study we examined the hypothesis that travelling increases the risk of tuberculosis, wasting 
syndrome, cryptosporidiosis, isosporiasis, cryptococcosis, coccidiomycosis, histoplasmosis and Salmonella 
septicaemia. A total of 4549 participants were included (in 1988-98) ofwhom 596 (13’ 1%) travelled at least 
once. During 16 800 person-years of follow-up 23 1 patients developed at least 1 of the diseases of interest. 
Wasting syndrome was the only diagnosis significantly associated with travelling (hazard ratio 2.16, 95% 
confidence interval 1.09 to 4.30). The risk ofwasting syndrome (‘slim disease’) should be taken into account 
when counselling HIV-infected patients intending to travel in tropical regions. 
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Introduction 
Travelling in tropical or subtropical regions may affect 
the health of HIV-infected people from countries with 
temperate climates (WILSON et al., 199 1). HIV-infected 
travellers may be at higher risk of contracting the 
conditions that are typically observed in travellers, for 
example traveller’s diarrhoea, and episodes may take a 
more severe course. The pattern ofAIDS-defining events 
in tropical countries differs from that in countries in 
moderate climate zones, and the risk of acquiring certain 
AIDS-defining conditions, most notably ‘slim disease’ 
(wasting syndrome) and tuberculosis, may thus be in- 
creased among HIV-infected travellers (GRANT et al., 
1997). We analysed the Swiss HIV Cohort Study to 
examine whether travelling in tropical countries in- 
creased the risk of progression to certain AIDS-defining 
conditions. 
Methods 
Study design and inclusion criteria 
Described in detail elsewhere (LEDERGERBER et al., 
1994) the Swiss HIV Cohort Study is a prospective 
cohort study based in 7 outpatient clinics. At each 6- 
monthly visit participants are asked whether they had 
travelled to a tropical or subtropical country. For the 
present analysis we included participants of Swiss na- 
tionality with a CD4+ cell count within 3 months of 
enrolment and at least 1 follow-up visit. We excluded 
patients with a history of AIDS (clinical stage C) at 
baseline and participants who did not belong to 1 of the 3 
main transmission groups (intravenous drug misuse, 
men who have sex with men and heterosexual contact). 
We examined whether the risk of 8 conditions, tubercu- 
losis, wasting syndrome, cryptosporidiosis, isosporiasis, 
cryptococcosis, coccidiomycosis, histoplasmosis, or Sal- 
monella septicaemia, was increased in travellers. Wasting 
syndrome- was defined as documented involuntary 
weight loss 0 10% from baseline) combined with either 
per&tent diarrhoea (at least 3 stools of reduced consis- 
tency per day for >30 days) or fever for >30 days without 
concurrent specific cause. Visits to a tropical or sub- 
tropical country were included as a time-dependent 
covariate in Cox models. This variable assumed the 
value 0 throughout in patients who never travelled to 
the tropics. In travellers tb.e variable switched to 1 as soon 
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as the first journey was recorded in the database. In 
additional analyses the dummy variable was allowed to 
increase with each completed journey. We stratified 
analyses by 3 calendar periods (1988-90, 1991-94 
and 1995-98) to allow baseline hazards to vary across 
periods. All analyses were adjusted for CD4+ cell count, 
clinical stage, transmission group and age at registration. 
Analyses were conducted using Stata software (version 
6.0. College Station. Texas. USA). Results are nresented 
as hazard zatios wi& 95% &nfid&ce interval (95% CI). 
Results 
A total of 4549 participants were eligible ofwhom 596 
(13.1%) had travelled to a tropical or subtropical coun- 
try; 381 participants travelled once, 122 twice and 93 
travelled at least 3 times, for a total of 1017 journeys. 
Participants were observed during 16 800 person-years 
(mean 3.69 years). Those who travelled were less likely to 
be intravenous drug misusers and had higher CD4+ cell 
counts at baseline (Table 1). Two-hundred and thirty- 
one patients developed at least 1 of the 8 infections of 
interest, with a total of 248 events recorded during 
follow-up. There was no statistically significant associa- 
tion of travelling in tropical or subtropical countries with 
any of these conditions except for wasting syndrome 
(Table 2). The adjusted hazard ratio for wasting was 2.16 
(95% CI 1.09 to 4.30). There was no significant 
association when the 8 conditions were considered as a 
group (adjusted hazard ratio 1*24,95% CI 0.81 to 1.89). 
Results were similar in analyses that took the number of 
journeys into account. The adjusted hazard ratio was 
1.10 (95% CI 0.89 to 1.35) per journey for all 8 
conditions and 1.37 (95% CI 1.02 to 1.83) per journey 
for wasting syndrome. Travelling in tropical or subtro- 
pical regions was associated with a lower rate of progres- 
sion to any AIDS-defining event. The adjusted hazard 
ratio was 0.77 (95% Cl 0.63 to 0.96). No significant 
association was evident for death from all causes (ad- 
justed hazard ratio 0.93, 95% CI 0.79 to 1.10). 
Discussion 
There is concern that HIV-infected patients travelling 
in tropical countries may experience clinical disease 
progression due to exposure to infectious agents, includ- 
ing mycobacteria, fungi and parasites. Based on theor- 
etical considerations and anecdotal or single-centre 
experiences most authors and expert committees have 
argued that travelling to tropical countries carries sub- 
stantial additional risks in HIV-infected travellers (WIL 
SON et al., 1991). We examined this issue in the Swiss 
HIV Cohort Study, a prospective study with national 
coverage which includes about 70% of AIDS cases 
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Table 1. Characteristics at baseline of HIV-infected study participants who did, or did 
not, travel to a tropical or subtropical country (Switzerland, 1988-98) 
Travelled Not travelled 
Characteristic (n = 596) (n = 3953) P 
Age (years) 33.1 (9.1) 33.2 (8.8) 0.88 
Gender 
Men 422 (70.8) 2774 (70.2) 0.75 
Women 174 (29.2) 1179 (29.8) 
Clinical stage < 0~0001 
A 473 (79.4) 2869 (72.6) 
B 123 (20.6) 1084 (27.4) 
Transmission group 0.008 
Intravenous drug misuse 188 (31.5) 1814 (45.9) 
Sex between men 239 (40.1) 1214 (30.7) 
Heterosexual contacts 169 (28.4) 925 (23.4) 
Year of enrolment < 0.000 1 
1988-90 305 (51.2) 1544 (39.1) 
1991-94 200 (33.6) 1324 (33.5) 
1995-98 91 (15.3) 1085 (27.4) 
CD4 cell count (X 106/L) 411 (121-861) 361 (91-831) 0.0005 
Numbers (%) are shown for gender, clinical stage, transmission group and year of enrolment with P-values from 
x2 tests, means (SD) are shown for age with the P-value from a z-test, and medians (90% ranges) are given for 
CD4 cell count with P-values from Wilcoxon rank-sum tests. 
Table 2. Relative hazard of Swiss HIV-infected patients developing events associated with travelling to 
tropical or subtropical countries: results for hypothesized high-risk conditions 
Hazard ratio (95% confidence interval) 
Number of 
Event patients Crude Adjusted” 
Tuberculosis 99 0.86 (0.41-1.80) 0.90 (0.43-1.90) 
Wasting syndrome 
:T 
2.03 (1.03-4.00) 2.16 (1.09-4.30) 
Cryptosporidiosis 1.28 (0.54-3.04) 1.35 (0.56-3.23) 
Cryptococcosis 20 1’ 12 (0.25-4.94) 0.98 (0.22-4-38) 
Salmonella septicaemia 7 1.52 (0.17-13.25) 1.64 (0.18-14.88) 
Isosporiasis 4 5.15 (0.49-53.56) 3.39 (0.32-35.60) 
Histoplasmosis 2 7.55 (0.47-121.34) 8.73 (0.37-203.40) 
Coccidiomycosis 0 - - 
“Adjusted for age, CD4+ cell count at baseline and during follow-up, CDC stage and transmission group. 
diagnosed in the country (LEDERGERBER et al, 1994; 
EGGER et al., 1997). Over 1000 trips were recorded 
among the 4549 patients included in this analysis, which 
demonstrates that travel to tropical regions is popular 
among people with HIV infection. 
Visits to tropical countries were associated with a lower 
risk of progression to AIDS, indicating that travelling is a 
proxy for good health. This phenomenon is analogous to 
the ‘healthy worker effect’ (FOX & COLLIER, 1976) in 
occupational epidemiology where selection bias may be 
introduced in comparisons with the general population 
by the fact that people who are able to work tend to be 
healthier. It is noteworthy that the hazard ratios of 7 out 
of the 8 conditions that we selected a priori were above 1, 
although only the association with wasting reached 
statistical significance. The fact that we were unable to 
control fully for what may be termed the ‘healthy traveller 
effect’ means that our analysis probably underestimates 
the strength of these associations. Such considerations 
are difficult to quantify but they underscore that the 
increased risk ofwasting should be of concern. Wasting is 
a relatively frequent condition in the later stages of HIV 
infection in industrialized countries (HOOVER et al., 
1993) and ‘slim disease’ is one of the most important 
AIDS-defining events in many African and other less- 
developed countries (GRANT et al., 1997). 
Our study has a number of limitations. First, it is 
possible that information on viral load would have 
allowed us to control for the ‘healthy traveller effect’; 
however, viral load measurements were introduced only 
recently. Secondly, the information collected on travels is 
rather crude. No data are available on the destination, the 
purpose and duration of the journey, or the style of 
travelling. Backpackers are known to be at higher risk to 
contract traveller’s diarrhoea than business travellers and 
tourists who stay in hotels that meet international 
standards (ERICSSON & DUPONT, 1993). These limit- 
ations mean that we are unable to provide estimates of 
the risk associated with travelling to tropical regions that 
take these factors into account. Thirdly, tourism in 
tropical regions may be followed by chronic diarrhoea, 
weight loss and fever even in immunocompetent people 
(STEFFEN et al., 1999). About 2% of travellers with 
diarrhoea suffer symptoms for more than 1 month after 
their return and this chronic course is often associated 
with significant weight loss (ERICSSON & DUPONT, 
1993). Chronic diarrhoea may be due to infection with 
Giardia intestinalis, Yersinia spp. or Campylobacter spp., 
or due to metabolic complications such as lactose intol- 
erance. New pathogens, for example Cyclospora cayeta- 
nensis or protozoa and viruses that are not defined at 
present, may lead to self-limiting episodes in immuno- 
competent hosts but to chronic diarrhoea in HIV- 
infected travellers (THEA et al., 1993; WEBER et al., 
1999). The diagnosis of wasting syndrome is based on 
the presence of chronic fever, weight loss and diarrhoea, 
after exclusion of specific aetiological agents. This diag- 
nosis could thus have been incorrect if not every possible 
pathogen was excluded in thorough examinations (WIL- 
COX et al., 1996). Finally, our study excluded patients 
with AIDS at enrolment and our results cannot be 
applied to these patients. 
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In conclusion, our results underscore the importance 
of preventive measures to avoid gastrointestinal infec- 
tions (ERICSSON & DUPONT, 1993; SIMONS et al., 
1999). When counselling HIV-infected patients prophy- 
lactic measures against food- and waterborne infections 
should be discussed in detail, in addition to addressing 
the possible need for vaccinations and chemoprophylaxis 
against malaria and, in exceptional cases, against travel- 
ler’s diarrhoea (DUPONT, 1993). With the advent of 
potent antiretroviral combination therapies more people 
with HIV may decide to spend their holidays in tropical 
regions. The impact of travelling in less-developed 
countries on adherence to and efficacy of combination 
therapies should be examined in future studies (COLB- 
BUNDERS et al., 1999). 
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